Table 2 Model variables: direct medical costs
| Â | Sensitivity analysis | |||
|---|---|---|---|---|
Base value ($) | Minimum ($) | Maximum ($) | Distribution ($) | |
TAS-102 | 1833.66516 | 1375.24887 | 2292.08145 | Gamma |
Bevacizumab | 767.945701 | 575.959276 | 959.932127 | Gamma |
Outpatient chemotherapy | Â | Â | Â | Â |
IV drip fee | 65.6108597 | 49.2081448 | 82.0135747 | Gamma |
Administration fee for chemotherapy | 36.199095 | 27.1493213 | 45.2488688 | Gamma |
Outpatient service fee | 6.60633484 | 4.95475113 | 8.25791855 | Gamma |
Prescription fee | 3.80090498 | 2.85067873 | 4.75113122 | Gamma |
Administration fee for chemotherapy(monotherapy) | 10.4072398 | 7.80542986 | 13.0090498 | Gamma |
Administration fee for chemotherapy (combination) | 220.633484 | 165.475113 | 275.791855 | Gamma |
Costs for management of complication (monotherapy) | 28.7519014 | 21.5639261 | 35.9398768 | Gamma |
Costs for management of complication (combination) | 72.0921038 | 54.0690778 | 90.1151297 | Gamma |